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Purpose or Objective: As of 1 July 2015 The 
ClinicalTrials.gov database was searched for interventional 
phase-3 trials in radiotherapy with a primary completion date 
before 1 January 2013. According to the 2007 Act of the 
FDAAA results of applicable clinical trials are due not later 
than 12 months after the primary completion date. Our 
objective was to determine how many of these trials have 
not been published a deposition of their results within the 
register yet. 
 
Material and Methods: A first study sample consisted of 802 
interventional phase-3 clinical trials with a primary 
completion date before 1 January 2013. We also took a 
sample which was a subset of the former one, taking into 
account only the interventional phase-3 clinical trials with a 
study start as of 1 January 2008; the main reason was to see 
if those trials starting after the 2007 Act publish more results 
within the register as the trials registered before the 2007 
Act was passed. 
 
Results: In our first study sample, a total of 655 trials 
(81.7%) did not deposit a summary result. Clinical Trials 
starting after the 2007 Act was passed did not do any better: 
422 out of 552 (76.4%) haven’t published a deposition of their 
results within the register. We further analyzed our search 
results taking into account the cancer subtype. The 
percentages of unpublished results for our second study 
sample were the following: Gastric (68%), Rectal (64%), 
Bladder (90%), Sarcoma (70%), Linfoma (78%), Esophagus 
(92%), Cervix (80.6%), Astrocitoma (70%), Testicular (100%), 
Skin (89.5%), Eye (47%), Anal (100%), Palliative (75%), 
Glioblastoma (62.5%), Breast (78%), Lung (73.7%), Head&Neck 
(74.6%), Prostate (68. %). 
 
Conclusion: Our results show that most trials do not report 
results, even if they are forced to do so after the 2007 Act. 
This means that a large number of study participants were 
exposed to the risks of trial participation without the 
supposed benefits that sharing and publishing results would 
have for future generations of patients. 
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Purpose or Objective: The aim of this prospective study was 
to determine any changes in brain metastases or resection 
cavity volumes between the planning MRI and radiosurgical 
(RS) treatment and if these impacted on management or led 
to an alteration of the RS plan. 
 
Material and Methods: 33 patients with 42 metastases and 12 
tumour resection cavities underwent a planning MRI (MRI-1) 
which was fused to the planning CT. GTV (metastasis) or CTV 
(cavity) were contoured from the T1 and T2 post-gadolinium 
MRI. The GTV/CTV had a 2mm circumferential expansion 
creating a PTV with a plan generated. In addition, a 
verification MRI (MRI-2) was performed 24-48 hours prior to 
RS with volumes re-contoured on MRI-2 (verGTV/verPTV). The 
GTV/CTV and PTV volume changes between MRI-1 and MRI-2 
were recorded and the original plan assessed for coverage of 
the verPTV. A change in plan or management based on MRI-2 
was recorded. 
 
Results: Patient and tumour characteristics are shown in 
Table 1. The median time between MRI-1 and MRI-2 was 7 
days with 27 patients (82%) having 14 days or less and 22 
patients (66%) with 7 days or less. Changes in GTV/CTV and 
PTV volumes between MRI-1 and MRI-2 are shown in Figure 1. 
19 (58%) patients required a change in management based on 
changes in lesions on MRI-2 including: re-planning of RS, or a 
change in treatment to whole-brain radiotherapy (WBRT), 
surgery or best supportive care (BSC). Per lesion, 30 out of 54 
lesions (56%) required re-planning based on MRI-2 including 5 
(42%) cavities and 25 (60%) metastases. 2 patients had rapid 
progression with lepto-meningeal disease diagnosed on MRI-2 
and received WBRT. 1 patient (previously received WBRT) 
had a rapid increase in lesion size and number, with an 
additional 9 lesions noted on MRI-2 and received BSC. 
Reasons for re-planning included: increase in volume (27 
lesions) with 25 verGTV lying outside the original PTV and 2 
touching the original PTV; 2 lesions with a reduction in 
verGTV/verPTV volumes, and 3 patients with an increase in 
the number of metastases or leptomeningeal disease on MRI-
2. 
 
Conclusion: This study is the first to demonstrate changes in 
brain metastases volume from planning MRI to RS treatment, 
where changes often occurred with an interval of 7 days or 
less. An MRI performed within 24-48 hours of RS led to re-
planning or a change in management in more than 50% of 
patients. Therefore, even a short interval between planning 
MRI and RS may result in a geographical miss or over 
treatment, emphasising the need for efficient planning 
processes. 
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Purpose or Objective: The aim of this study was an 
evaluation of a toxicity and an early effectiveness of prostate 
cancer patients CyberKnife based radioablation.  
 
Material and Methods: 350 PC patients (186 Low Risk, 164 
Intermediate Risk) aged from 53 to 83 (mean 69) irradiated 
with CK every other day (fd 7.25Gy, TD 36.25Gy, OTT 9 
days). Before the treatment start PSA varied from 0.3 to 19.5 
(median 7.5) and T stage from T1c to T2c. Mean prostate 
dimensions were 42.6x37.2x41.1mm. FU ranged to 48 months 
(mean 12). Directly after the treatment, 1, 4, 8 months later 
and the next every 6 months, the percentage of patients with 
Androgen Deprivation Therapy (ADT), GI (gastro-intestinal) 
and GU (genito-urinary) toxicity (acute up to the 4th month 
and the next late) using the EORTC/RTOG scale and PSA 
concentration were checked.  
 
Results: The percentage of patients without ADT increased 
from 42.6% to 100% 32 months later. The maximal percentage 
of acute G3 adverse effects was 0.5% for GI, 0.6% for GU and 
G2 – 1.9% for GI and 6.0% for GU. No G3 late toxicity was 
observed. The maximal percentage of late G2 toxicity was 
0.5% for GI and 3.0% for GU. PSA median decreased from 2.2 
to 0.2 ng/ml during FU. One patient relapsed (18 months 
after RT- next treated with salvage BT) and one developed 
metastasis in lymphatic node (treated next with salvage CK). 
The detailed results are presented in the Table.  
 
 
 
 
 
 
 
 
 
 
 
 
 
